Gene
FGFR4
FGFR4 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (5), Actionable biomarkers (1), Trial mentions (23), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention FGFR4. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 2 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 2 of 8,738 | 0.02% | not measured | |
| 2025 | 6 of 8,875 | 0.07% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 14 of 11,460 | 0.12% |
| 2022 | 3 of 8,285 | 0.04% | 18 of 13,598 | 0.13% |
| 2021 | 3 of 8,692 | 0.03% | 21 of 15,045 | 0.14% |
| 2020 | 2 of 7,640 | 0.03% | 17 of 14,459 | 0.12% |
| 2019 | 1 of 7,300 | 0.01% | 16 of 12,159 | 0.13% |
| 2018 | 2 of 6,927 | 0.03% | 12 of 11,854 | 0.10% |
| 2017 | 1 of 6,558 | 0.02% | 12 of 11,595 | 0.10% |
Showing 10 of 37 years.
Assay-provider ledger (5)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Agilent Technologies | Reagent supplier | Clinical validation | 1 | May 01, 2020 |
| AVIVA SYSTEMS BIOLOGY | Reagent supplier | Clinical validation | 1 | May 01, 2020 |
| Sigma Aldrich | Reagent supplier | Clinical validation | 1 | May 01, 2020 |
| DropSens, S.L. | Reagent supplier | Analytical validation | 1 | Date unknown |
| R & D Systems | Reagent supplier | Analytical validation | 1 | Date unknown |
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| FGFR4 (N535,V550) | Fgfr Inhibitors | response-associated | rhabdomyosarcoma | Cancer Genome Interpreter |
Trial mentions (23)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02325739 | Trial eligibility (AACT) |
| NCT04699643 | Trial eligibility (AACT) |
| NCT04962867 | Trial eligibility (AACT) |
| NCT07327034 | Trial eligibility (AACT) |
| NCT04565275 | Trial eligibility (AACT) |
Showing 5 of 23 trial mentions.
Target-disease associations (385)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Ampulla of Vater Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Anaplastic (Malignant) Meningioma | cancer or benign tumor | Cancer Gene Census |
| Atypical Meningioma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 385 associations.
Vendor sourcing (59)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Abbisko Therapeutics Co., Ltd. (China) | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | : Prior/Concomitant Therapy * 1\. Has received any systemic chemotherapy, including anti-VEGF therapy, or any systemic investigational anticancer agents fo... | View trial NCT07010497 |
| Abbisko Therapeutics Co., Ltd. (China) | Trial collaborator | Mentioned in trial textTrial free-text mention | FGFR4 | View trial NCT07010497 |
| Abbisko Therapeutics Co., Ltd. (China) | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : 1. Known allergies or hypersensitivity to any component of the investigational product (ABSK-011 or placebo). 2. Previous treatment with selective FGFR4 i... | View trial NCT07327034 |
| Abbisko Therapeutics Co., Ltd. (China) | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : 1. Known allergy or hypersensitivity to any component of the investigational drug product. 2. Previous treatment with FGFR4 or pan-FGFR pathway inhibitors... | View trial NCT04906434 |
| Abbisko Therapeutics Co., Ltd. (China) | Trial sponsor | Mentioned in trial textTrial free-text mention | FGFR4 | View trial NCT04906434 |
Showing 5 of 59 sourcing records.
Trial-cited literature (173)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum-based treatment: A phase 1/2 trial. | Cancer | 2025 | 2 |
| Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer. | Cancer research communications | 2025 | 0 |
| Pathogenesis of allergic diseases and implications for therapeutic interventions. | Signal transduction and targeted therapy | 2023 | 286 |
| Signalling cognition: the gut microbiota and hypothalamic-pituitary-adrenal axis. | Frontiers in endocrinology | 2023 | 276 |
| A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. | JHEP reports : innovation in hepatology | 2023 | 84 |
Showing 5 of 173 papers.
Protein variant mentions (5)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.G388R | 7 | 2010 to 2022 | PMID 35360655, PMID 32088296, PMID 32562118 |
| p.P136L | 1 | 2010 | PMID 20691689 |
| p.S591F | 1 | 2023 | PMID 36787089 |
| p.V10I | 1 | 2010 | PMID 20691689 |
| p.Y751F | 1 | 2015 | PMID 26437603 |
Literature-extracted relations (24)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Chenodeoxycholic Acid | Chemical | associate |
Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. | 2010 |
| Imatinib | Chemical | negative_correlate |
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. | 2000 |
| (LMW)heparin | Chemical | associate |
FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. | 1999 |
| Diarrhea | Disease | associate |
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. | 2023 |
| Neoplasms | Disease | associate |
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. | 2023 |
Showing 5 of 24 relation assertions.
Organizations publishing (210)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Mayo Clinic | Hospital | 12 | 2010 to 2022 |
| CERCA Institution | Government | 7 | 2014 to 2023 |
| The University of Texas System | Academic | 7 | 2008 to 2022 |
| Memorial Sloan Kettering Cancer Center | Hospital | 6 | 2008 to 2023 |
| Dana-Farber Cancer Institute | Other | 5 | 2015 to 2020 |
Showing 5 of 210 organizations.
Where FGFR4 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- infectious disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
315 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.